Mumbai: Bal Pharma Ltd. Managing director, Sailesh Siroya recently intimidated the National Stock Exchange that the company after obtaining all the regulatory approvals as per Regulation 30 of SEBI(LODR) Regulations, the bulk drugs manufacturing unit at Udaipur has commenced its commercial production of intermediates and Active Pharma Ingredients (API).
The APL products which of scheduled to be manufactured at this Unit were developed by the company’s
R&D facility at Bangalore and due to capacity constraints at the Bangalore facility they could not become commercially viable till 3rd of December 2018.
This unit is expected to ease the capacity concerns of API’s and intermediates and will cater to the North are Northeastern markets of the country and also overseas markets.
To recapitulate, the company has acquired 100% shareholding and management control of Golden Drugs Pvt Ltd, Udaipur, Rajasthan, which is into manufacturing of API’s and intermediates, during March 2018.
Bal Pharma shares climbed nearly 6 per cent after the commencement of commercial production at Udaipur unit.
Bal Pharma is one of the leading Indian pharmaceutical companies that focuses on prescription drugs, generic, OTC products, intravenous infusion and bulk actives.
Also Read: Bal Pharma acquires Golden Drugs Pvt Ltd